All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Our anti-CD22 CAR-T products are designed for researchers to study the efficacy and mechanism of CAR-T therapy in preclinical or in vitro assays. Please browse the following list to find a suitable product.
CD22, also known as sialic acid-binding immunoglobulin-like lectin 2 (Siglec-2), is a transmembrane protein that is primarily expressed on the surface of B cells. CD22 is a member of the immunoglobulin superfamily and acts as an inhibitory co-receptor for B cell receptor (BCR) signaling. CD22 can inhibit the activation of B cells and prevent overactivation of the immune system. CD22 also plays a role in modulating immune tolerance and preventing autoimmunity. It can interact with B cell co-receptor CD19, thereby fine-tuning B cell activities and regulating the threshold for B cell activation. Additionally, CD22 has been implicated in the regulation of B cell survival, trafficking, and maturation. The overexpression of CD22 is associated with certain types of B cell malignancies, such as diffuse large B cell lymphoma (DLBCL), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML), which make it an attractive target for antibody-based and cell-based therapies.
Fig.1 3D structure of CD22 molecule.1
Associated Disease
Monitoring and optimizing CAR expression levels and functionality are important during the development and manufacturing process of CAR T-cell therapies. We provide anti-CD22 CAR expression tests to confirm that the CD22 CAR construct has been successfully incorporated into the T cells.
Fig.2 Expression of CD22 CAR on T cells surface.2
Monitoring CAR-T cell proliferation is important for optimizing the effectiveness and safety of CAR-T cell therapies. We provide various in vitro CAR-T cell proliferation assays that can determine the ability of CAR-T cell proliferation and guide further optimization and development of CAR-T cell therapies.
Fig.3 Proliferation of CD22 CAR-T cells.3
Cytokine release tests provide insights into the cytokine profiles associated with CAR-T response to specific stimuli. We perform cytokine release tests including ELISA and multiplex immunoassays to measure the levels of cytokine release.
Fig.4 ELISA detection of cytokine release.2
In vitro cytotoxicity assays are commonly used to evaluate the anti-tumor activity of CAR-T cells. We utilize several methods to assess anti-CD22 CAR-T cytotoxicity in vitro, including LDH release assay, MTT assay, and Chromium-51 Release Assay.
Fig.5 The in vitro killing efficacy of CD22 CAR-T cells against various B-cell malignant cells.2
In order to evaluate anti-tumor efficacy of CAR-T therapy in vivo, we generate animal models implanted with tumors to assess the therapeutic effect of CAR-T cells in killing the tumor. CAR-T cells are then administered to the mice, and tumor growth, regression, and immune response are assessed.
Fig.6 Antitumor effect of CD22 CAR-T cells in vivo.2 (A) Schematic of in vivo evaluation model of CAR-T; (B) IVIS imaging of tumor growth.
Anti-CD22 CAR-T Cell Persistence Test
The CAR-T cell persistence test is used to evaluate the ability of CAR-T cells to persist and remain functional over a long period. We provide CAR-T cell persistence test services to monitor the levels of CAR-T cells in the blood or other tissues over time, typically by q-PCR or flow cytometry techniques.
Fig.7 CD22 CAR copy numbers in blood over time.2
References
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-LC061 | Anti-CD22 (HA22) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | HA22 | Mouse | scFv-CD28-CD3ζ | Retroviral | T cell | ||
CAR-LC062 | Anti-CD22 (HA22) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | HA22 | Mouse | scFv-CD28-41BB-CD3ζ | Retroviral | T cell | ||
CAR-LC063 | Anti-CD22 (HA22) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | HA22 | Mouse | scFv-41BB-CD3ζ | Retroviral | T cell | ||
CAR-LC064 | Anti-CD22 (BL22) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | BL22 | Mouse | scFv-CD28-CD3ζ | Retroviral | T cell | ||
CAR-LC065 | Anti-CD22 (BL22) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 | Human | BL22 | Mouse | scFv-CD28-41BB-CD3ζ | Retroviral | T cell | ||
CAR-SB-LX0078 | Anti-CD22 (Pinatuzumab) h(CD28-CD3ζ) CAR, pSBCAR1 | Human | Pinatuzumab | Humanized | scFv-CD28-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
CAR-SB-LX0079 | Anti-CD22 (Bectumomab) h(CD28-CD3ζ) CAR, pSBCAR1 | Human | Bectumomab | Mouse | scFv-CD28-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
CAR-SB-LX0081 | Anti-CD22 (Moxetumomab) h(CD28-CD3ζ) CAR, pSBCAR1 | Human | Moxetumomab | Mouse | scFv-CD28-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
CAR-SB-LX0082 | Anti-CD22 (Inotuzumab) h(CD28-CD3ζ) CAR, pSBCAR1 | Human | Inotuzumab | Mouse | scFv-CD28-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
CAR-MV-01LX010 | Anti-CD22 (HA22) h(CD28-CD3ζ) CAR, pMMLV | Human | HA22 | Mouse | scFv-CD28-CD3ζ | Recombinant Moloney murine leukemia virus (MMLV) retroviral vector | T cell | ||
CAR-MV-01LX011 | Anti-CD22 (BL22) h(CD28-CD3ζ) CAR, pMMLV | Human | BL22 | Mouse | scFv-CD28-CD3ζ | Recombinant Moloney murine leukemia virus (MMLV) retroviral vector | T cell | ||
CAR-MV-01LX012 | Anti-CD22 (HA22SH) h(CD28-CD3ζ) CAR, pMMLV | Human | HA22SH | Mouse | scFv-CD28-CD3ζ | Recombinant Moloney murine leukemia virus (MMLV) retroviral vector | T cell | ||
CAR-MV-01LX255 | Anti-CD22 (HA22) h(41BB-CD3ζ) CAR, pMMLV | Human | HA22 | Mouse | scFv-41BB-CD3ζ | Recombinant Moloney murine leukemia virus (MMLV) retroviral vector | T cell | ||
CAR-MV-01LX256 | Anti-CD22 (BL22) h(41BB-CD3ζ) CAR, pMMLV | Human | BL22 | Mouse | scFv-41BB-CD3ζ | Recombinant Moloney murine leukemia virus (MMLV) retroviral vector | T cell | ||
CAR-MV-01LX257 | Anti-CD22 (HA22SH) h(41BB-CD3ζ) CAR, pMMLV | Human | HA22SH | Mouse | scFv-41BB-CD3ζ | Recombinant Moloney murine leukemia virus (MMLV) retroviral vector | T cell | ||
CAR-SB-02LX009 | Anti-CD22 (HA22) h(CD28-41BB-CD3ζ) CAR, pSBCAR1 | Human | HA22 | Mouse | scFv-CD28-41BB-CD3ζ | Sleeping Beauty (SB) transposon | T cell | ||
XS-0823-LX14 | Anti-hCD22 (L22) ICD(CD28-OX40-CD3ζ) CAR-MA, pAd5f35 Vector | Human | L22 | Adenoviral vectors |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION